The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a ...

Corcept sees 40% growth in 2025 revenue with promising trials, expanded patient base, and strong projections. Read my ...

The firm said it based the decision on the announcement of successful Phase 3 ROSELLA study results in platinum-resistant ovarian cancer. While we acknowledge the potential of Corcept Therapeutics ...

INX-315, a CDK2 inhibitor, gained FDA fast track status in CCNE1-positive platinum-resistant/refractory ovarian cancer.

Northwestern Medicine scientists have identified a key driver of chemotherapy resistance in advanced ovarian cancer, ...

Healthcare & Pharmaceuticalscategory· March 31, 2025 Corcept's ovarian cancer drug cuts disease progression in study, shares jump Corcept Therapeutics said on Monday its experimental drug in ...

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 Corcept Therapeutics Incorporated (NASDAQ: CORT), a ...

Corcept is studying relacorilant in a variety of serious disorders in addition to ovarian cancer, including endogenous hypercortisolism (Cushing’s syndrome) and prostate cancer. Relacorilant is ...